Agenix cuts COO position
Thursday, 27 October, 2005
Brad Calvin is to step down as chief operating officer of Agenix (ASX:AGX) today after the company decided not to renew his employment contract.
Agenix managing director Donald Home will take on Calvin's responsibilities.
The company said Calvin was initially employed to lead the sales and marketing of the Agenix's Animal Health, Human Health and Milton Pharmaceuticals businesses and to assist in the commercialisation of the company's ThromboView product.
Agenix has since divested Milton Pharmaceuticals and entered into an agreement for the global sales, marketing and distribution of ThromboView and the company decided that its requirements for the Animal and Human Health businesses "did not warrant the current level of staffing".
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
